Dr. Kin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4100 John R
Detroit, MI 48201Phone+1 313-576-8720
Summary
- I am board certified in hematology and oncology specializing in hematologic malignancies including myeloma, amyloidosis, lymphoma, bone marrow transplant and adoptive cellular therapy including CAR-T cell therapy.
Education & Training
Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 2015 - 2018
Ohio State University HospitalResidency, Internal Medicine, 2012 - 2015
University of Cincinnati College of MedicineClass of 2012
Certifications & Licensure
OH State Medical License 2012 - 2026
MI State Medical License 2015 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration Start of enrollment: 2019 Aug 13
- Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT Start of enrollment: 2020 Feb 20
- Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma Start of enrollment: 2020 Aug 17
Publications & Presentations
PubMed
- 41 citationsDaratumumab proves safe and highly effective in AL amyloidosis.Jack Khouri, Andrew Kin, Bicky Thapa, Frederic J. Reu, Naresh Bumma
British Journal of Haematology. 2019-04-01 - 5 citationsImproved post-ASCT survival of relapsed/refractory classical Hodgkin lymphoma patients in the era of novel agents.Harsh Shah, Hyejeong Jang, Paramveer Singh, Jorgena Kosti, Andrew Kin
Leukemia & Lymphoma. 2021-11-15 - 18 citationsElotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Re...Benjamin A Derman, Ankit Kansagra, Jeffrey Zonder, Andrew T Stefka, David L Grinblatt
JAMA Oncology. 2022-09-01
Abstracts/Posters
- Maintenance Therapy after Second Autologous Stem Cell Transplant in Multiple Myeloma Improves Overall SurvivalAndrew Kin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Use of Thymoglobulin with Lower Dose of Busulfan Results in Less Acute Gvhd Following Unrelated Donor Allogeneic Stem Cell Transplantation for AML without Affecting Re...Andrew Kin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Absolute Lymphocyte Count (ALC) Less Than 100 Predicts Adverse Transplant Outcomes with Rabbit Thymoglobulin in Patients Undergoing Matched Unrelated Allogeneic Hemato...Andrew Kin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
Graduating Fellow and Karmanos Breast Cancer Specialist Co-Author Manuscript on Triple Negative Breast Cancer with BMT FacultyOctober 18th, 2022- NexImmune Announces Preliminary Phase 1/2 NEXI-002 Results in Patients with Multiple MyelomaDecember 12th, 2021
OncLive® Presents the Latest State of the Science Summit™ on Hematologic MalignanciesSeptember 5th, 2018
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
